Author reply

Molina-Prat, Nicolás; Saint-Jean, Alejandro; Maza, Maite Sainz de la

doi:10.1016/j.ophtha.2012.12.024

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, there has yet to be an agreement in the use of autologous serum eye drops as being a beneficial action during EGFR-I treatment [ 5 ]. Molina-Prat et al [ 11 ] believe that the use of autologous serum eye drops may not be effective with concomitant use of EGFR-I, but instead only effective after EGFR-I discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib

Gozzi

Tiseo

Facchinetti

et al. 2021

Case Rep Ophthalmol

View full text Add to dashboard Cite

We describe the case of Gefitinib-related bilateral corneal perforation. An 86-year-old female patient had bilateral painless and progressive vision loss due to neurotrophic corneal ulcer, following a 2-month treatment with Gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for metastatic adenocarcinoma of the lung with confirmed EGFR gene mutation. She had no signs of ocular infection, inflammation, or lid problems to account for the development of corneal damage. Neurotrophic ulcer evolved into a frank perforation in one eye and an impending perforation on the other eye. EGFR inhibitors have been associated with dry eye, epithelial erosions, ulcerative keratitis, and corneal edema. However, to the best of our knowledge, this is the first case of bilateral severe corneal ulcer due to Gefitinib. The patient went on to have bilateral corneal graft surgery. This case aims to raise awareness among ophthalmologists and oncologists of the association between EGFR inhibitors, corneal neurotrophic ulcers, and possible evolution in corneal perforation.

show abstract

Section: Discussionmentioning

confidence: 99%